Published: 3 June 2021
Publications
Recent approvals: new active ingredients or new indications
Published: 3 June 2021
Prescriber Update 42(2): 29
June 2021
For the period 16 January 2021 to 15 April 2021.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Comirnaty (COVID-19 mRNA vaccine) | Concentrate for injection 0.5 mg/mL |
Immunisation to prevent COVID-19 |
| Mayzent (siponimod) | Film coated tablet 0.25 mg 2 mg |
Multiple sclerosis |
| Vyvanse (lisdexamfetamine) | Capsule 30 mg 50 mg 70 mg |
Attention deficit hyperactivity disorder (ADHD) |
Approved medicines with new indications
| Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Forxiga (dapagliflozin) | Film coated tablet 10 mg |
Chronic kidney disease |
| Opdivo (nivolumab) | Concentrate for infusion 40 mg/4 mL 100 mg/10 mL |
Non-small cell lung cancer |
| Sirturo (bedaquiline) | Tablet 100 mg |
Tuberculosis in paediatric patients (aged 12 years to less than 18 years) |
| Sprycel (dasatinib) | Film coated tablet 20 mg 50 mg 70 mg 100 mg |
Paediatric patients with Philadelphia
chromosome positive: · chronic myeloid leukaemia · acute lymphoblastic leukaemia |
| Toujeo (neutral insulin) | Solution for injection 300 IU/mL |
Diabetes mellitus in patients aged 6 years and older |
See the Medsafe website for:
